Poster
Matching-Adjusted Indirect Comparison (MAIC) of Mobocertinib vs Amivantamab in Patients with Non-Small Cell Lung Cancer (NSCLC) with EGFR Exon 20 Insertions (ex20ins)
Author
Sai-Hong I Ou
Condition
Non-Small Cell Lung Cancer
Drug target
EGFR Exon 20 insertions
Date
2021
Source url
s3://convoke-optic-posters/9371cf3c-d7a2-46a8-b58e-6f2bb96443d5.pdf
7 organizations
1 product
Product
Mobocertinib, AmivantamabOrganization
Chao Family Comprehensive Cancer Center, University of California Irvine School of MedicineOrganization
Evidera, IncOrganization
Takeda Pharmaceuticals America, IncOrganization
City of Hope National Medical CenterOrganization
Stanford Cancer Institute